Arcturus Therapeutics

ARCT

時価総額 $2.94億

RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance innovative treatments targeting a range of diseases.

Arcturus Therapeutics NASDAQ: ARCT presented preliminary Phase II data for ARCT-810, its mRNA therapeutic candidate for ornithine transcarbamylase, or OTC, deficiency, while outlining plans to introduce a next-generation delivery platform into the program.

Arcturus Therapeutics Holdings Inc. (ARCT) Discusses Phase II Data for OTC Deficiency and Advances in mRNA Liver Therapeutics Platform Transcript

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company,” “Arcturus,” Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeutics, today announced encouraging interim Phase 2 results from ARCT-810 in ornithine transcarbamylase (OTC) deficiency and introduced LUNAR 2.0™, the Company's next-generation mRNA delivery platform, and additional liver pipeline programs. “The ARCT-810 Phase 2 interim results validate Arcturus' m.

Arcturus Therapeutics is advancing mRNA-based therapies, with ARCT-810 for OTC deficiency as a near-term catalyst and ARCT-032 for cystic fibrosis in phase 2. ARCT-810 has shown promising phase 2 interim data, normalizing glutamine and ammonia levels, and is designated Orphan Drug, Fast Track, and Rare Pediatric Disease by the FDA. The upcoming Sep. 23 presentation on ARCT-810 could be stock-moving, but small trial sizes mean results should be viewed as hypothesis-generating.

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will host a virtual presentation on Wednesday, September 23, 2026, at 4:30 p.m. ET. The presentation will provide an overview of the ARCT-810 Phase 2 clinical program for Ornithine transcarbamylase (OTC) deficiency and Arcturus' mRNA liver therapeutics pl.

Arcturus Therapeutics Holdings Inc. (ARCT) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will participate in the following investor conferences: Wells Fargo 21st Annual Healthcare Conference (Boston) | Fireside Chat September 8, 2026 (2:15 p.m. ET) Citi's 2026 Biopharma Back to School Conference (New York) | Fireside Chat September 9.

After reaching an important support level, Arcturus Therapeutics Holdings Inc. (ARCT) could be a good stock pick from a technical perspective. ARCT recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

Arcturus Therapeutics NASDAQ: ARCT is positioning its mRNA platform around two rare-disease programs targeting cystic fibrosis and ornithine transcarbamylase deficiency, while its vaccine business is intended to help support therapeutic development, President and CEO Joseph Payne said during a Canaccord discussion.